A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations

Axel Bex, Laurence Albiges, Michael Staehler, Karim Bensalah, Rachel H. Giles, Saeed Dabestani, Fabian Hofmann, Milan Hora, Markus A. Kuczyk, Thomas B. Lam, Lorenzo Marconi, Axel S. Merseburger, Sergio Fernández-Pello, Rana Tahbaz, Yasmin Abu-Ghanem, Alessandro Volpe, Börje Ljungberg, Bernard Escudier, Thomas Powles*

*Corresponding author for this work
3 Citations (Scopus)
Original languageEnglish
JournalEuropean Urology
Issue number6
Pages (from-to)849-851
Number of pages3
Publication statusPublished - 12.2018

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)

Cite this